Joseph Tien Seng Wee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph Tien Seng Wee has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Melvin Lee Kiang Chua
National Cancer Centre Singapore/Duke-NUS Medical School, Singapore
6 shared publications - Yoke Lim Soong
Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
6 shared publications - Sze Huey Tan
Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore
4 shared publications Sharon S. Poh
Division of Radiation Oncology, National Cancer Centre Singapore, Oncology ACP, Duke-NUS Medical School, Singapore
3 shared publicationsSharon Shuxian Poh
3 shared publications- Sharon Shuxian Poh
National Cancer Centre Singapore
3 shared publications
Latest Publications
- Open Access
- 5 December 2023
- Published by Elsevier in Oral Oncology
- Vol. 148, 106655
Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma
- 5 December 2023
- Published by Elsevier in Oral Oncology
- Vol. 148, 106655
Open AccessLongitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma
- 1 January 2023
- Published by Medknow in Journal of Head & Neck Physicians and Surgeons
- Vol. 11 (1) , 1-7
Dr. PA Shah Oration 2022
- 1 January 2023
- Published by Medknow in Journal of Head & Neck Physicians and Surgeons
- Vol. 11 (1) , 1-7
Dr. PA Shah Oration 2022
- Open Access
- 1 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 42 (9) , 801-803
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward
- 1 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 42 (9) , 801-803
Open AccessNasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward
- Open Access
- 6 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 41 (5) , 361-370
Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives
Click on the article title to read more.
- 6 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 41 (5) , 361-370
Open AccessRetreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives
Click on the article title to read more.
- Open Access
- 1 January 2021
- Published by AME Publishing Company in Annals of Nasopharynx Cancer
- Vol. 5
EBV and NPC carcinogenesis—an alternative viewpoint
- 1 January 2021
- Published by AME Publishing Company in Annals of Nasopharynx Cancer
- Vol. 5
Open AccessEBV and NPC carcinogenesis—an alternative viewpoint
- 1 November 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (3) , 567-580
International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma
- 1 November 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (3) , 567-580
International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma
- Top Cited Papers
- 1 June 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 291 (3) , 677-686
Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma
An artificial intelligence–based contouring tool improved tumor target contouring accuracy for nasopharyngeal carcinoma, which could have a positive impact on tumor control and patient survival. BackgroundNasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly variable among radiation oncologists.PurposeTo construct and validate an artificial intelligence (AI) contouring tool to automate primary gross tumor volume (GTV) contouring in patients with NPC.Materials and MethodsIn this retrospective study, MRI data sets covering the nasopharynx from 1021 patients (median age, 47 years; 751 male, 270 female) with NPC between September 2016 and September 2017 were collected and divided into training, validation, and testing cohorts of 715, 103, and 203 patients, respectively. GTV contours were delineated for 1021 patients and were defined by consensus of two experts. A three-dimensional convolutional neural network was applied to 818 training and validation MRI data sets to co...
- 1 June 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 291 (3) , 677-686
Top Cited PapersDeep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma
An artificial intelligence–based contouring tool improved tumor target contouring accuracy for nasopharyngeal carcinoma, which could have a positive impact on tumor control and patient survival. BackgroundNasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly variable among radiation oncologists.PurposeTo construct and validate an artificial intelligence (AI) contouring tool to automate primary gross tumor volume (GTV) contouring in patients with NPC.Materials and MethodsIn this retrospective study, MRI data sets covering the nasopharynx from 1021 patients (median age, 47 years; 751 male, 270 female) with NPC between September 2016 and September 2017 were collected and divided into training, validation, and testing cohorts of 715, 103, and 203 patients, respectively. GTV contours were delineated for 1021 patients and were defined by consensus of two experts. A three-dimensional convolutional neural network was applied to 818 training and validation MRI data sets to co...
- Open Access
- 12 November 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1095
Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC
Inter-patient heterogeneity in radiation-induced DNA damage responses is proposed to reflect intrinsic variations in tumour and normal tissue radiation sensitivity, but the prediction of phenotype by a molecular biomarker is influenced by clinical confounders and assay reproducibility. Here, we characterised the intrapatient and inter-patient heterogeneity in biomarkers of DNA damage and repair and radiation-induced apoptosis. We enrolled 85 of 172 patients with locally advanced nasopharynx cancer from a randomised controlled phase II/III trial of induction chemotherapy added to chemo-radiotherapy. G0 blood lymphocytes were harvested from these patients, and irradiated with 1, 4, and 8 Gy ex vivo. DNA damage induction (1 Gy 0.5 h) and repair (4 Gy 24 h) were assessed by duplicate γH2AX foci assays in 50–100 cells. Duplicate FLICA assays performed at 48 h post-8 Gy were employed as surrogate of radiation-induced apoptosis; %FLICA-positive cells were quantified by flow cytometry. We observed limited intrapatient variation in γH2AX foci and %FLICA readouts; median difference of duplicate foci scores was − 0.37 (IQR = − 1.256-0.800) for 1 Gy 0.5 h and 0.09 (IQR = − 0.685-0.792) for 4 Gy 24 h; ICC of ≥0.80 was observed for duplicate %FLICA0Gy and %FLICA8Gy assays of CD4+ and CD8+ T lymphocytes. As expected, we observed wide inter-patient heterogeneity in both assays that was independent of intrapatient variation and clinical covariates, with the exception of age, which was inversely correlated with %FLICAbackground-corrected (Spearman R = − 0.406, P < 0.001 [CD4+]; R = − 0.220, P = 0.04 [CD8+]). Lastly, an exploratory case-control analysis indicates increased levels of γH2AX foci at 4 Gy 24 h in patients with severe late radiotherapy-induced xerostomia (P = 0.05). Here, we confirmed the technical reproducibility of DNA damage response assays for clinical implementation as biomarkers of clinical radiosensitivity in nasopharynx cancer patients.
- 12 November 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1095
Open AccessIntra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC
Inter-patient heterogeneity in radiation-induced DNA damage responses is proposed to reflect intrinsic variations in tumour and normal tissue radiation sensitivity, but the prediction of phenotype by a molecular biomarker is influenced by clinical confounders and assay reproducibility. Here, we characterised the intrapatient and inter-patient heterogeneity in biomarkers of DNA damage and repair and radiation-induced apoptosis. We enrolled 85 of 172 patients with locally advanced nasopharynx cancer from a randomised controlled phase II/III trial of induction chemotherapy added to chemo-radiotherapy. G0 blood lymphocytes were harvested from these patients, and irradiated with 1, 4, and 8 Gy ex vivo. DNA damage induction (1 Gy 0.5 h) and repair (4 Gy 24 h) were assessed by duplicate γH2AX foci assays in 50–100 cells. Duplicate FLICA assays performed at 48 h post-8 Gy were employed as surrogate of radiation-induced apoptosis; %FLICA-positive cells were quantified by flow cytometry. We observed limited intrapatient variation in γH2AX foci and %FLICA readouts; median difference of duplicate foci scores was − 0.37 (IQR = − 1.256-0.800) for 1 Gy 0.5 h and 0.09 (IQR = − 0.685-0.792) for 4 Gy 24 h; ICC of ≥0.80 was observed for duplicate %FLICA0Gy and %FLICA8Gy assays of CD4+ and CD8+ T lymphocytes. As expected, we observed wide inter-patient heterogeneity in both assays that was independent of intrapatient variation and clinical covariates, with the exception of age, which was inversely correlated with %FLICAbackground-corrected (Spearman R = − 0.406, P < 0.001 [CD4+]; R = − 0.220, P = 0.04 [CD8+]). Lastly, an exploratory case-control analysis indicates increased levels of γH2AX foci at 4 Gy 24 h in patients with severe late radiotherapy-induced xerostomia (P = 0.05). Here, we confirmed the technical reproducibility of DNA damage response assays for clinical implementation as biomarkers of clinical radiosensitivity in nasopharynx cancer patients.
- 12 April 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (8) , 1824-1833
Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials
Purpose: Because of the uneven geographic distribution and small number of randomized trials available, the value of additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) remains controversial. This study performed an individual patient data (IPD) pooled analysis to better assess the precise role of IC + CCRT in locoregionally advanced NPC. Experimental Design: Four randomized trials in endemic areas were identified, representing 1,193 patients; updated IPD were obtained. Progression-free survival (PFS) and overall survival (OS) were the primary and secondary endpoints, respectively. Results: Median follow-up was 5.0 years. The HR for PFS was 0.70 [95% confidence interval (CI), 0.56–0.86; P = 0.0009; 9.3% absolute benefit at 5 years] in favor of IC + CCRT versus CCRT alone. IC + CCRT also improved OS (HR = 0.75; 95% CI, 0.57–0.99; P = 0.04) and reduced distant failure (HR = 0.68; 95% CI, 0.51–0.90; P = 0.008). IC + CCRT had a tendency to improve locoregional control compared with CCRT alone (HR = 0.70; 95% CI, 0.48–1.01; P = 0.06). There was no heterogeneity between trials in any analysis. No interactions between patient characteristics and treatment effects on PFS or OS were found. After adding two supplementary trials to provide a more comprehensive overview, the conclusions remained valid and were strengthened. In a supplementary Bayesian network analysis, no statistically significant differences in survival between different IC regimens were detected. Conclusions: This IPD pooled analysis demonstrates the superiority of additional IC over CCRT alone in locoregionally advanced NPC, with the survival benefit mainly associated with improved distant control. Clin Cancer Res; 24(8); 1824–33. ©2018 AACR.
- 12 April 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (8) , 1824-1833
Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials
Purpose: Because of the uneven geographic distribution and small number of randomized trials available, the value of additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) remains controversial. This study performed an individual patient data (IPD) pooled analysis to better assess the precise role of IC + CCRT in locoregionally advanced NPC. Experimental Design: Four randomized trials in endemic areas were identified, representing 1,193 patients; updated IPD were obtained. Progression-free survival (PFS) and overall survival (OS) were the primary and secondary endpoints, respectively. Results: Median follow-up was 5.0 years. The HR for PFS was 0.70 [95% confidence interval (CI), 0.56–0.86; P = 0.0009; 9.3% absolute benefit at 5 years] in favor of IC + CCRT versus CCRT alone. IC + CCRT also improved OS (HR = 0.75; 95% CI, 0.57–0.99; P = 0.04) and reduced distant failure (HR = 0.68; 95% CI, 0.51–0.90; P = 0.008). IC + CCRT had a tendency to improve locoregional control compared with CCRT alone (HR = 0.70; 95% CI, 0.48–1.01; P = 0.06). There was no heterogeneity between trials in any analysis. No interactions between patient characteristics and treatment effects on PFS or OS were found. After adding two supplementary trials to provide a more comprehensive overview, the conclusions remained valid and were strengthened. In a supplementary Bayesian network analysis, no statistically significant differences in survival between different IC regimens were detected. Conclusions: This IPD pooled analysis demonstrates the superiority of additional IC over CCRT alone in locoregionally advanced NPC, with the survival benefit mainly associated with improved distant control. Clin Cancer Res; 24(8); 1824–33. ©2018 AACR.
- 1 January 2018
- Published by AME Publishing Company in Annals of Nasopharynx Cancer
- Vol. 1 (4) , 1
Thoughts on Beta-integrins and a postulated pathogenesis for nasopharyngeal carcinoma
The Epstein-Barr virus (EBV) has been definitively implicated in the development of nasopharyngeal cancer (NPC). However, little is known about how specifically EBV gains entry into the cells to effect carcinogenic change, and why this affects certain ethnic populations more than others. The current dogma regarding EBV infection in NPC has been that of late infection, followed by multiple postulated mechanisms for immune evasion of EBV against the host defences, leading to eventual trigger of carcinogenesis. This paper postulates that beta-integrin 6, which is primarily expressed during embryonic development and possibly in neonatal life, may play a role in the development of NPC by facilitating entry of EBV into cells within the nasopharynx during the perinatal period, and this, coupled with ethnic differences in cell—mediated and innate immunity, leads to latent infection within the nasopharynx. Subsequent accumulation of further environmental and/or oncogenic changes leads to the eventual development of NPC in the patient in later life.
- 1 January 2018
- Published by AME Publishing Company in Annals of Nasopharynx Cancer
- Vol. 1 (4) , 1
Thoughts on Beta-integrins and a postulated pathogenesis for nasopharyngeal carcinoma
The Epstein-Barr virus (EBV) has been definitively implicated in the development of nasopharyngeal cancer (NPC). However, little is known about how specifically EBV gains entry into the cells to effect carcinogenic change, and why this affects certain ethnic populations more than others. The current dogma regarding EBV infection in NPC has been that of late infection, followed by multiple postulated mechanisms for immune evasion of EBV against the host defences, leading to eventual trigger of carcinogenesis. This paper postulates that beta-integrin 6, which is primarily expressed during embryonic development and possibly in neonatal life, may play a role in the development of NPC by facilitating entry of EBV into cells within the nasopharynx during the perinatal period, and this, coupled with ethnic differences in cell—mediated and innate immunity, leads to latent infection within the nasopharynx. Subsequent accumulation of further environmental and/or oncogenic changes leads to the eventual development of NPC in the patient in later life.